LDS/Medical Tests/Methaqualone, Urine

Methaqualone, Urine

Methaqualone is a quinazoline derivative that was introduced originally in 1951as an antimalarial drug and shortly thereafter as a sedative-hypnotic drug that was considered a safe alternative to barbiturates. It was a very popular drug of abuse in the 1960s and 1970s. It produced a feeling of euphoria without drowsiness, unlike barbiturates. It was removed from use by 1984 and is rarely observed today in the U.S. Its use and availability is currently observed most often in South America, where it is used in combination with diphenhydramine (Mandrax).

The typical route of administration is oral, but it is also crushed and smoked with cannabis. Methaqualone is extensively metabolized by hydroxylation and glucuronide conjugation. There are more than 12 hydroxylated metabolites known to be excreted in the urine, along with 2-nitrobenzo-o-toluidide and the glucuronide conjugates. The half-life of methaqualone ranges from 20-60 hours

Approximately half of a methaqualone dose is eliminated within 72 hours of a dose. Actual elimination depends on factors such as drug formulation, dose, dose frequency, clinical status and pharmacokinetics of the individual patient. Detection of methaqualone use has been reported as long as 29 days after a single dose, when the detection limit of the test was 1 ng/mL.

Common side effects: sedation, drowsiness, aphrodisiac, paresthesia, reduced heart rate, reduced respiration, slurred speech, photophobia, headache. Can be addictive. Overdose effects include respiratory depression, delirium, convulsions, hypertonia, renal failure, coma, cardiac arrest, and possible death.

Methaqualone and metabolites can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available, although are not commonly detected in most laboratory drug panels.

Methaqualone is currently illegal in the U.S. and is used only for recreational purposes.

  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A qualitative positive result indicates only the presence of Methaqualone and does not necessarily correlate with the extent of physiological and psychological effects, nor does it predict the dose that was taken or administered. Any result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method.

Therapeutic levels: 0.1-0.2 mg/L
Toxic levels: Data not available

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration is preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection or laboratory, whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report.

Limited methods are available but historically have included Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), Thin Layer Chromatography (TLC), or Immunoassay (IA). A pre-analytical hydrolysis reaction to liberate the glucuronide conjugates may improve detection.

Fresh urine specimen (random) collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 7-14 days
  • Frozen: 30 days
Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Foster City, CA: Biomedical Publications; 2011.
  • Levine B (ed). Miscellaneous Central Nervous System Depressants. In: Principles of Forensic Toxicology, 4th ed. Washington DC: AACC Press; 2013: 261-270.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.